KZR KEZAR LIFE SCIENCES INC Investments/Divestments 8-K Filing 2023 - Collaboration and License Agreement with Everest Medicines II (HK) Limited Kezar Life Sciences, Inc. entered into a Collaboration and License Agreement with Everest Medicines II (HK) Limited for the development and commercialization of their proprietary compound in the greater China region and other countries, with potential milestone payments of up to $125.5 million and tiered royalties on net sales.Get access to all SEC 8-K filings of the KEZAR LIFE SCIENCES INC